

# With Very Low LDL, HDL Is Not a Marker

BY SHARON WORCESTER

FROM THE LANCET

**H**igh-density lipoprotein cholesterol concentrations are inversely associated with risk for cardiovascular events, but this association does not persist in patients who achieve very low concentrations of low-density lipoprotein cholesterol on statin therapy, according to an analysis of data from the

JUPITER (Justification for the Use of Statins in Primary Prevention) trial.

In 8,901 patients in the study who received placebo and who had a median LDL cholesterol level of 2.8 mmol/L (108 mg/dL), HDL cholesterol levels were inversely associated with risk for cardiovascular events both at baseline and on placebo (hazard ratios, 0.54 and 0.55, respectively, for the top vs. the bottom quartiles of HDL cholesterol levels).

However, in 8,900 patients in the study who were treated daily with 20 mg rosuvastatin (Crestor) and who had a median LDL cholesterol level of 1.42 mmol/L (55 mg/dL) on treatment, there was no significant association between HDL cholesterol concentrations and vascular risk at baseline or on treatment (hazard ratios, 1.12 and 1.03, respectively, for the top vs. bottom quartiles of HDL cholesterol levels), Dr. Paul M. Rid-

ker of Brigham and Women's Hospital, Boston and his colleagues reported.

They also noted that, like HDL cholesterol levels, apolipoprotein A1 levels were strongly and inversely associated with risk for cardiovascular events in the placebo group, but these associations were attenuated and not statistically significant in the treatment group.

Patients were part of the JUPITER trial, which enrolled 17,802 participants from March 2003 to December 2006 to investigate whether rosuvastatin lowered the rate of first-ever cardiovascular events.

Study participants had LDL cholesterol levels of less than 3.4 mmol/L (130 mg/dL) and were at high vascular risk

REGISTER NOW

WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

Earn up to  
12 Credits  
of CME

Rheumatology News®, Internal Medicine News®, & Family Practice News® PRESENT

A CONTINUING MEDICAL EDUCATION CONFERENCE

PERSPECTIVES IN RHEUMATIC DISEASES 2010™

October 22-23, 2010

Loews Santa Monica Beach Hotel  
Santa Monica, California

**CHAIR Daniel E. Furst, MD**

Carl M. Pearson Professor of Medicine  
Department of Medicine, Division of Rheumatology  
David Geffen School of Medicine at the  
University of California, Los Angeles (UCLA)

**CO-CHAIR Kenneth B. Gordon, MD**


Clinical Associate Professor of Dermatology  
University of Chicago The Pritzker School of Medicine  
Head, Division of Dermatology  
NorthShore University HealthSystems  
Skokie, Illinois

#### Registration

Physicians	\$395
Physician Assistant	\$295
Nurse Practitioner	\$295
Residents	\$250
Industry (Non-exhibitor)	\$595

#### Hotel Accommodations

Loews Santa Monica Beach Hotel  
1700 Ocean Avenue  
Santa Monica, California 90401  
Phone: (310) 458-6700  
Fax: (310) 458-6761  
www.santamonicaloewshotel.com  
Mention **Rheumatology Conference** for preferred rates.



#### FACULTY

**Jeffrey Benabio, MD** University of California, San Diego  
**Russell D. Cohen, MD** The University of Chicago Medical Center  
**Andrew H. Eichenfield, MD** Presbyterian Columbia University Medical Center  
**Jeffrey P. Callen, MD** University of Louisville  
**Sherine E. Gabriel, MD, MSc** Mayo Clinic  
**Brian Mandell, MD, PhD** The Cleveland Clinic  
**Philip J. Mease, MD** University of Washington School of Medicine  
**Joan T. Merrill, MD** Oklahoma Medical Research Foundation  
**Amanda E. Nelsen, MD** University of North Carolina  
**Ronald J. Oudiz, MD** University of California, Los Angeles

#### PROGRAM HIGHLIGHTS

Biologics and Rheumatoid Arthritis  
Cardiovascular Issues and RA  
Psoriasis and Psoriatic Arthritis  
SLE and Cutaneous Lupus  
Managing Pain: Fibromyalgia  
Crohn's Disease, IBD and RA  
Osteoarthritis • Vasculitis  
Hyperuricemia and Gout  
Systemic Sclerosis and Pulmonary Hypertension  
Rheumatic Diseases in Children

#### FEATURING

Case sessions: 360 Degrees: A Multi-Specialty Approach  
Build Your Practice with Social Media

#### LEARNING OBJECTIVES

At the conclusion of this conference, participants will be able to:

- Describe the long-term safety and efficacy of biologic and other systemic agents in the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis.
- Explain the connection between rheumatic diseases and cardiovascular risk.
- Outline the clinical course of SLE and cutaneous lupus; explain the importance and benefit of early treatment.
- Identify the aspects of care, treatment, and overall outcomes that are important in the management of pediatric patients with rheumatic diseases.
- Develop a strategy for a diagnostic workup to accurately establish (or rule out) fibromyalgia as a cause of a patient's symptoms.
- Apply the most current information regarding the risk factors for, the clinical manifestations of, and the cutting-edge treatments for hyperuricemia and gout.
- Compare and contrast the efficacy and safety profiles of pharmacologic therapeutic options for osteoarthritis and identify their limitations.
- Identify and describe the clinical manifestations and complications of systemic sclerosis and pulmonary hypertension.

#### ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville (CHSE) and Skin Disease Education Foundation (SDEF). CHSE is accredited by the ACCME to provide continuing medical education (CME) for physicians.

#### AMA PRA CREDIT DESIGNATION STATEMENT

The CHSE designates this educational activity for a maximum of 12 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### AAFP CREDIT

This activity has been reviewed and is acceptable for up to 11.75 Prescribed credits by the American Academy of Family Physicians.

#### NURSING CREDIT

This program has been approved by the Kentucky Board of Nursing for 14.4 contact hours through the University of Louisville School of Nursing, provider number 3-0046-01-2013-141, expiration date January 31, 2013. Complete contact information is posted at [www.rheumatologynewsperspectives.com](http://www.rheumatologynewsperspectives.com).

FOR FULL CONFERENCE DETAILS: WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

JOINTLY SPONSORED BY



Supported, in part, with educational grants  
from ABBOTT, ACTELION, CENTOCOR,  
GILEAD, LILLY AND URL PHARMA.



Global Academy for  
Medical Education  
an Elsevier business

**VITALS** **Major Finding:** In 8,900 patients treated daily with 20 mg rosuvastatin and who had a median LDL cholesterol level of 1.42 mmol/L on treatment, there was no significant association between HDL levels and vascular risk at baseline or on treatment (hazard ratios, 1.12 and 1.03, respectively, for the top vs. bottom quartile of HDL levels).

**Data Source:** An analysis of the randomized, double-blind, placebo-controlled JUPITER trial.

**Disclosures:** AstraZeneca, maker of the trial drug, funded the study. Dr. Ridker reported receiving grant support and/or consulting and lecture fees from AstraZeneca and other drug manufacturers. He is listed as a co-inventor on patents held by the Brigham and Women's Hospital, which relate to the use of inflammatory biomarkers in cardiovascular disease and have been licensed to AstraZeneca and other entities. Some authors also reported receiving research support and/or consulting and lecture fees from AstraZeneca and numerous drug manufacturers.

because of elevated high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or more, but were otherwise healthy, without cardiovascular disease or diabetes.

Indeed, rosuvastatin reduced LDL levels to a median of 1.4 mmol/L (55 mg/dL), with 25% of patients achieving concentrations of less than 1.1 mmol/L (44 mg/dL) in the trial, and treatment was associated with a 54% reduction in MI, a 48% reduction in stroke, a 46% reduction in revascularization, and a 20% reduction in total mortality (N. Engl. J. Med. 2008;359:2195-20), the investigators noted.

Now, based on the findings of the current analysis of data from the JUPITER primary prevention trial, it appears that treatment also reduces the clinical relevance of HDL cholesterol concentrations, they said (Lancet 2010 July 22 [doi:10.1016/S0140-6736(10)60713-1]).

"This analysis provides little evidence that residual risk after aggressive use of  
*Continued on following page*



Continued from previous page

statin therapy is related to HDL-cholesterol concentration," the investigators wrote, noting that their findings are supported by similar findings in one other primary prevention trial and two secondary prevention trials involving high-dose statin therapy.

The current study is strengthened by the investigators' ability to adjust for a wide range of covariates, including age, sex, smoking status, metabolic syndrome, family history of premature atherosclerosis, body mass index, systolic blood pressure, fasting glucose, and estimated glomerular filtration rate. Analyses of HDL cholesterol were controlled for baseline concentrations of LDL cholesterol, triglyceride, and hsCRP (and in the case of on-treatment HDL cholesterol, for changes in the latter three), they said.

The study is limited, however, by the exclusion of diabetic patients and the inclusion of patients with LDL cholesterol of less than 3.4 mmol/L. Generalization of the findings should therefore be done with caution, they noted.

The investigators concluded that their primary prevention data, along with data from other primary and secondary prevention studies, provide little evidence in support of the hypothesis that HDL cholesterol concentrations predict risk of vascular events in patients on high-dose statins.

They noted, however, that their findings should not "reduce enthusiasm for measurement [of HDL cholesterol concentration] as part of an initial cardiovascular risk assessment."

Future randomized trials of potent HDL cholesterol-raising agents are needed to determine if such treatment would provide added benefit in terms of cardiovascular risk reduction in patients whose LDL levels are successfully lowered on statin therapy, they said.

In an accompanying editorial comment, Dr. Derek Hausenloy of the Hatter Cardiovascular Institute at University College London Hospital and his colleagues noted that although the researchers had shown that HDL cholesterol concentrations do not predict residual cardiovascular risk in patients with very low LDL cholesterol concentrations, the reasons for this observation remain unclear (Lancet 2010 July 22 [doi:10.1016/S0140-6736(10)61021-5]).


"Perhaps, in patients with a low cardiovascular risk ... who are treated to very low concentrations of LDL cholesterol, the relation between HDL cholesterol and cardiovascular risk is lessened; however, [the researchers] were not able to find a relation between apolipoprotein A1 and reduced cardiovascular risk," the commentators wrote.

They added that in the setting of very low LDL cholesterol, other lipid measures, such as apolipoprotein B to A1 ratio, may provide a better prediction of cardiovascular risk.

Regardless, the findings should not "detract from the fact that raising HDL cholesterol remains a major treatment strategy for the reduction of cardiovas-

cular risk in the large majority of patients who do not have very low LDL cholesterol," wrote Dr. Hausenloy and his colleagues, none of whom had any disclosures to make in relation to the study.

It still needs to be determined in large randomized trials whether increasing HDL cholesterol in patients with very low LDL cholesterol is of benefit, they noted, adding that such trials will be particularly important given that two new inhibitors of cholesterol ester transfer proteins—anacetrapib and dalcetrapib—are now in clinical testing. ■



Take on the mealtime challenge

And help your patients improve glycemic control with NovoLog®, the #1 selling rapid-acting mealtime insulin.<sup>1</sup>

Model is for illustrative purposes only.

NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

#### Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. **When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent.** Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

To access complimentary e-learning programs, visit [novomedlink.com/NovoLog](http://novomedlink.com/NovoLog).



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.  
© 2009 Novo Nordisk Inc. 137970

June 2009



**NovoLog®**  
insulin aspart (rDNA origin) injection